Fagron N.V. : Softer H2 22 REBITDA but 7.5% FCF yield attractive
>H1 22 recap: Higher FY22 sales guide, but soft H1 22 REBITDA - Fagron reported a mixed set of H1 22 results, with on the positive side a 4% sales beat, continued strong operating cash flow, good EMEA Compounding Services performance (back to growth), and a 3% higher FY22 sales guide versus consensus (€ 670-690m; excluding the impact from the recently acquired Boston 503B facility). The weaker than expected reported H1 22 REBITDA (2% miss) and the soft FY22 REBITDA gu...Fagron supplies products, services to professionals and institutions in the healthcare sector in Europe, the U.S.A. and Brazil. Co.'s activities are subdivided into four divisions. Through Fagron, Co. offers products and concepts for pharmaceutical compounding. Through Arseus Dental, Co. supplies dental products and concepts to dentists and dental laboratories in Belgium, the Netherlands, France, Germany and Switzerland. Through Arseus Medical, Co. supplies medical and surgical products to specialists, elderly homes, homecare nurses and hospitals in Belgium and the Netherlands. Through Corilus, Co. supplies ICT total solutions for medical specialists in Belgium, the Netherlands and France.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.